Recently Viewed
Clear All$201.66
$1.30
(0.65%)
As on 24-Mar-2026 16:00EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$4,084 Mln
Revenue (TTM)
$268 Mln
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
P/E Ratio
33.5
P/B Ratio
4
Industry P/E
--
EV/EBITDA
19.1
Div. Yield
0 %
Debt to Equity
0.4
Book Value
$48.1
EPS
$5.9
Face value
--
Shares outstanding
19,941,141
CFO
$704.40 Mln
EBITDA
$-240.05 Mln
Net Profit
$1,153.96 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
| 6.7 | 9.8 | 2.2 | 86.5 | 43.1 | 15.8 | 11.9 |
|
BSE Sensex
| -12.5 | -11.1 | -13.4 | -3.7 | 8.5 | 8.2 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
| 76.5 | 49.5 | 6.9 | -30.7 | 55.3 | -4.6 | -23.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
201.7 | 4,084.1 | 268.1 | 124.5 | 60.0 | 13.5 | 33.5 | 4.0 |
| 11.3 | 3,410.4 | 510.2 | 146.9 | 37.2 | 35.6 | 23.9 | 7.2 | |
| 12.1 | 3,722.1 | 3,018.8 | 72.1 | 12.6 | -80 | 53.8 | 86.1 | |
| 158.8 | 8,027.0 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.0 | |
| 68.5 | 13,287.4 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 33.8 | 3,684.8 | 761.4 | 99.7 | 7.3 | 15 | 42.2 | 5.7 | |
| 13.5 | 11,772.8 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 19.6 | 3.0 | |
| 24.9 | 11,922.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.9 | |
| 7.6 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 35.2 | 3,208.3 | 158.3 | -68.9 | -29.3 | -113 | -- | 71.7 |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA... and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida. Read more
President & COO
Mr. Matthew E. Korenberg
President & COO
Mr. Matthew E. Korenberg
Headquarters
Jupiter, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ligand Pharmaceuticals Incorporated (LGND) is $201.66 (NASDAQ) as of 24-Mar-2026 16:00 EDT. Ligand Pharmaceuticals Incorporated (LGND) has given a return of 43.14% in the last 3 years.
The P/E ratio of Ligand Pharmaceuticals Incorporated (LGND) is 33.47 times as on 20-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
32.11
|
3.93
|
|
2024
|
-504.23
|
2.45
|
|
2023
|
24.21
|
1.80
|
|
2022
|
-33.82
|
1.89
|
|
2021
|
29.19
|
2.03
|
The 52-week high and low of Ligand Pharmaceuticals Incorporated (LGND) are Rs 227.92 and Rs 93.58 as of 25-Mar-2026.
Ligand Pharmaceuticals Incorporated (LGND) has a market capitalisation of $ 4,084 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ligand Pharmaceuticals Incorporated (LGND), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.